Literature DB >> 1138629

Results of ankle ststolic pressure measurements in patients with intermittent claudication being treated with clofibrate.

J C Postlethwaite, J A Dormandy.   

Abstract

Ankle systolic pressure measurements in 67 patients with intermittent claudication treated with Clofibrate for an average period of 11 months and 32 untreated patients suggest that 1) patients with a raised initial plasma fibrinogen concentration have more severe disease than those with low initial plasma fibrinogen concentration and 2) the response to treatment with Clofibrate is significantly better in those with a raised plasma fibrinogen concentration. On the basis of the patients own estimation of their claudication distance there was marked symptomatic inprovement in the treated patients. There was also a significant decrease in mean plasma fibrinogen levels in the treated patients and it is suggested that the hypofibrinogenemic effect of Clofibrate may be responsible for the benefit of this drug in patients with vascular disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138629      PMCID: PMC1343897          DOI: 10.1097/00000658-197506000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  10 in total

1.  THE EFFECT OF ATROMID ON PLASMA FIBRINOGEN AND HEPARIN RESISTANCE.

Authors:  R C COTTON; E G WADE; G W SPILLER
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec

2.  Prognostic significance of rheological and biochemical findings in patients with intermittent claudication.

Authors:  J A Dormandy; E Hoare; A H Khattab; D E Arrowsmith; T L Dormandy
Journal:  Br Med J       Date:  1973-12-08

3.  Simultaneouus flow and pressure measurements in intermittent claudication.

Authors:  J D Lewis; C Papathanaiou; S T Yao; H H Eastcott
Journal:  Br J Surg       Date:  1972-06       Impact factor: 6.939

4.  Influence of blood viscosity on blood flow and the effect of low molecular weight dextran.

Authors:  J A Dormandy
Journal:  Br Med J       Date:  1971-12-18

5.  Haemodynamic studies in peripheral arterial disease.

Authors:  S T Yao
Journal:  Br J Surg       Date:  1970-10       Impact factor: 6.939

6.  Ankle systolic pressure measurements in arterial disease affecting the lower extremities.

Authors:  S T Yao; J T Hobbs; W T Irvine
Journal:  Br J Surg       Date:  1969-09       Impact factor: 6.939

7.  Clinical nephelometry. 1. New, accurate, heat-precipitation nephelometric method for rapid determination of plasma fibrinogen.

Authors:  E W Rice; D E Muesse
Journal:  Clin Chem       Date:  1972-01       Impact factor: 8.327

8.  Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.

Authors:  H A Dewar; M F Oliver
Journal:  Br Med J       Date:  1971-12-25

9.  Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication.

Authors:  J A Dormandy; E Hoare; J Colley; D E Arrowsmith; T L Dormandy
Journal:  Br Med J       Date:  1973-12-08

10.  Effect of clofibrate on blood viscosity in intermittent claudication.

Authors:  J A Dormandy; J M Gutteridge; E Hoare; T L Dormandy
Journal:  Br Med J       Date:  1974-11-02
  10 in total
  4 in total

1.  The importance of plasma fibrinogen in vascular surgery.

Authors:  J C Postlethwaite
Journal:  Ann R Coll Surg Engl       Date:  1976-11       Impact factor: 1.891

Review 2.  Intermittent claudication. An update on management.

Authors:  P A Blombery
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Current therapy for intermittent claudication.

Authors:  M Verstraete
Journal:  Drugs       Date:  1982-09       Impact factor: 9.546

4.  The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.

Authors:  G D Calvert; L Blight; J Franklin; J Oliver; P Wise; A S Gallus
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.